Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Oronsky B, Reid TR, Oronsky A, Carter CA (2017) What’s new in SCLC? A review. Neoplasia 19:842–847. https://doi.org/10.1016/j.neo.2017.07.007

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang S, Tang J, Sun T et al (2017) Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep 7:1339. https://doi.org/10.1038/s41598-017-01571-0

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer 121:664–672. https://doi.org/10.1002/cncr.29098

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929–1939. https://doi.org/10.1016/s0140-6736(19)32222-6

Article  CAS  PubMed  Google Scholar 

Cheun H, Kim M, Lee H et al (2019) Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. Invest New Drug 37:579–583. https://doi.org/10.1007/s10637-018-0673-y

Article  Google Scholar 

Thurlow JS, Joshi M, Yan G et al (2021) Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol 52:98–107. https://doi.org/10.1159/000514550

Article  PubMed  Google Scholar 

Na SY, Sung JY, Chang JH et al (2011) Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol 33:121–130. https://doi.org/10.1159/000323740

Article  PubMed  Google Scholar 

Maisonneuve P, Agodoa L, Gellert R et al (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354:93–99. https://doi.org/10.1016/s0140-6736(99)06154-1

Article  CAS  PubMed  Google Scholar 

Janus N, Thariat J, Boulanger H et al (2010) Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 21:1395–1403. https://doi.org/10.1093/annonc/mdp598

Article  CAS  PubMed  Google Scholar 

Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493–507. https://doi.org/10.2165/11531280-000000000-00000

Article  CAS  PubMed  Google Scholar 

Centanni M, Moes DJAR, Trocóniz IF et al (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58:835–857. https://doi.org/10.1007/s40262-019-00748-2

Article  PubMed  PubMed Central  Google Scholar 

Imaji M, Fujimoto D, Kato M et al (2021) Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature. Respirol Case Reports 9:e00741. https://doi.org/10.1002/rcr2.741

Article  Google Scholar 

Ishizuka S, Sakata S, Yoshida C et al (2018) Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression. Respir Investig 56:361–364. https://doi.org/10.1016/j.resinv.2018.03.005

Article  PubMed  Google Scholar 

Osa A, Uenami T, Naito Y et al (2019) Monitoring antibody binding to T cells in a pembrolizumab-treated patient with lung adenocarcinoma on hemodialysis. Thorac Cancer 10:2183–2187. https://doi.org/10.1111/1759-7714.13197

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strohbehn IA, Lee M, Seethapathy H et al (2020) Safety and efficacy of immune checkpoint inhibitors in patients on dialysis: a retrospective case series. Am J Kidney Dis 76:299–302. https://doi.org/10.1053/j.ajkd.2020.02.451

Article  CAS  PubMed  PubMed Central  Google Scholar 

Funakoshi T, Horimatsu T, Nakamura M et al (2018) Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open 3:e000301. https://doi.org/10.1136/esmoopen-2017-000301

Article  PubMed  PubMed Central  Google Scholar 

Wang J, Dasari S, Elantably D et al (2022) Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data. Acta Oncol 61:1157–1161. https://doi.org/10.1080/0284186x.2022.2127121

Article  CAS  PubMed  Google Scholar 

Yanagita M, Muto S, Nishiyama H et al (2023) Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol. https://doi.org/10.1007/s10157-023-02415-0

Article  PubMed  PubMed Central  Google Scholar 

Leung TV, Hughes ME, Cambareri CG et al (2018) Systemic treatments for lung cancer patients receiving hemodialysis. J Adv Pract Oncol 9:614–629

PubMed  PubMed Central  Google Scholar 

Krens SD, Lassche G, Jansman FGA et al (2019) Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol 20:e200–e207. https://doi.org/10.1016/s1470-2045(19)30145-7

Article  CAS  PubMed  Google Scholar 

Takezawa K, Okamoto I, Fukuoka M, Nakagawa K (2008) Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. J Thorac Oncol 3:1073–1075. https://doi.org/10.1097/jto.0b013e318183af89

Article  PubMed  Google Scholar 

Belani CP, Kearns CM, Zuhowski EG et al (1999) Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non–small-cell lung cancer. J Clin Oncol 17:676–676. https://doi.org/10.1200/jco.1999.17.2.676

Article  CAS  PubMed  Google Scholar 

Kim YH, Mio T, Hamamoto Y, Mishima M (2010) Successful treatment with carboplatin and etoposide in a small-cell lung cancer patient undergoing hemodialysis. Respir Med Cme 3:68–70. https://doi.org/10.1016/j.rmedc.2009.05.006

Article  Google Scholar 

Inoue A, Saijo Y, Kikuchi T et al (2004) Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 15:51–54. https://doi.org/10.1093/annonc/mdh008

Article  CAS  PubMed  Google Scholar 

Watanabe M, Aoki Y, Tomita M et al (2002) Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol 84:335–338. https://doi.org/10.1006/gyno.2001.6527

Article  PubMed  Google Scholar 

Chatelut E, Rostaing L, Gualano V et al (1994) Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron 66:157–161. https://doi.org/10.1159/000187794

Article  CAS  PubMed  Google Scholar 

Oguri T, Shimokata T, Inada M et al (2010) Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Cancer Chemother Pharmacol 66:813–817. https://doi.org/10.1007/s00280-010-1366-1

Article  CAS  PubMed  Google Scholar 

Oguri T, Shimokata T, Ito I et al (2015) Extension of the Calvert formula to patients with severe renal insufficiency. Cancer Chemother Pharmacol 76:53–59. https://doi.org/10.1007/s00280-015-2769-9

Article  CAS  PubMed  Google Scholar 

Shimokata T, Ando Y, Yasuda Y et al (2010) Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci 101:2601–2605. https://doi.org/10.1111/j.1349-7006.2010.01729.x

Article  CAS  PubMed  Google Scholar 

Hatta T, Hase T, Hara T et al (2023) Adjustment of creatinine clearance for carboplatin dosing in Calvert’s formula and clinical efficacy for lung cancer. Cancer Med 12:15955–15969. https://doi.org/10.1002/cam4.6235

Article  CAS  PubMed  PubMed Central  Google Scholar